Cohance Lifesciences Limited (NSE:COHANCE)

Market Cap	390.14B
Revenue (ttm)	12.59B
Net Income (ttm)	2.41B
Shares Out	382.57M
EPS (ttm)	9.40
PE Ratio	108.54
Forward PE	69.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	291,747
Average Volume	811,686
Open	1,019.40
Previous Close	1,019.80
Day's Range	977.30 - 1,020.70
52-Week Range	856.30 - 1,360.00
Beta	0.64
RSI	61.22
Earnings Date	Nov 7, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 1,212
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: COHANCE

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.